Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. The company is headquartered in Stockholm, Stockholm and currently employs 1,888 full-time employees. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
最新の財務諸表(Form-10K)によると、Swedish Orphan Biovitrum AB (publ)の総資産は$67,434で、純利益は$478です。
BIOVFの主要な財務比率は何ですか?
Swedish Orphan Biovitrum AB (publ)の流動比率は2.26、純利益率は1.69、1株当たり売上高は$80.99です。
Swedish Orphan Biovitrum AB (publ)の収益はセグメントまたは地域別にどのように分けられていますか?
Swedish Orphan Biovitrum AB (publ) の最大収益セグメントは Haematology で、最新の利益発表における収益は 13,370,000,000 です。地域別に見ると、United States が Swedish Orphan Biovitrum AB (publ) の主要市場であり、収益は 8,148,000,000 です。
Swedish Orphan Biovitrum AB (publ)は収益を上げていますか?
はい、最新の財務諸表によると、Swedish Orphan Biovitrum AB (publ)の純利益は$478です。
Swedish Orphan Biovitrum AB (publ)に負債はありますか?
はい、Swedish Orphan Biovitrum AB (publ)の負債は29,717です。
Swedish Orphan Biovitrum AB (publ)の発行済株式数は何株ですか?
Swedish Orphan Biovitrum AB (publ)の総発行済株式数は345.66株です。